Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Immunicum AB (1YG0) Stock Price & Analysis

1 Followers

1YG0 Stock Chart & Stats

€0.42-€0.01(-2.09%)
At close: 5:30 PM GMT+1
€0.5€0.75€1Nov 20Jan 18Dec 16May 6Oct 14May 12Nov 6
Day’s Range
EUR 0.41 - EUR 0.43
52-Week Range
EUR 0.35 - EUR 0.65
Previous Close
EUR 0.43
Volume
N/A
Average Volume (3M)
29
Market Cap
EUR 28.04M
Enterprise Value
EUR 355.78M
Total Cash (Recent Filing)
EUR 59.88M
Total Debt (Recent Filing)
EUR 17.93M
Price to Earnings (P/E)
―
Beta
0.32
Next Earnings
Feb 11, 2027 (Est.)
EPS Estimate
-0.04
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage preserves financial flexibility because the company carries limited debt obligations relative to equity. This reduces balance-sheet pressure and leaves more capacity to direct available resources toward clinical development while managing the volatility typical of an early-stage biotechnology business.

Narrowing Losses

Narrower losses indicate some improvement in cost absorption or operating discipline, even though profitability has not been reached. If sustained, this trend could extend the company’s financial runway and reduce the pace at which its equity base is consumed while development programs continue.

Improved Cash Burn

Improvement in cash burn compared with 2023 is a constructive operating trend because it suggests spending has become more controlled. Although cash generation remains negative, a lower burn rate can preserve funding capacity for longer and support continued advancement of the company’s immuno-oncology programs.

Bears Say

No Recurring Revenue

The absence of a consistent revenue base means the company currently lacks operating income to absorb research, development, and corporate costs. This leaves financial progress dependent on external funding or future product success, making the business model less self-sustaining over the next several quarters.

Persistent Cash Burn

Persistent negative operating and free cash flow shows that current activities consume rather than generate cash. Even with improved burn versus 2023, continued funding needs can constrain development choices and increase reliance on future financing before the pipeline produces commercial returns.

Equity Erosion

Negative returns on equity combined with a shrinking equity base show that ongoing losses are reducing shareholder capital rather than generating value from it. Continued erosion can weaken financial resilience over time and limit the resources available to support long-duration clinical development.

Immunicum AB News

1YG0 FAQ

What was Immunicum AB’s price range in the past 12 months?
Immunicum AB lowest stock price was €0.35 and its highest was €0.65 in the past 12 months.
What is Immunicum AB’s market cap?
Immunicum AB’s market cap is €28.04M.
When is Immunicum AB’s upcoming earnings report date?
Immunicum AB’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 89 days.
How were Immunicum AB’s earnings last quarter?
Immunicum AB released its earnings results on Nov 11, 2026. The company reported -€0.032 earnings per share for the quarter, beating the consensus estimate of -€0.043 by €0.012.
Is Immunicum AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Immunicum AB pay dividends?
Immunicum AB does not currently pay dividends.
What is Immunicum AB’s EPS estimate?
Immunicum AB’s EPS estimate is -0.04.
How many shares outstanding does Immunicum AB have?
Immunicum AB has 64,784,580 shares outstanding.
What happened to Immunicum AB’s price movement after its last earnings report?
Immunicum AB reported an EPS of -€0.032 in its last earnings report, beating expectations of -€0.043. Following the earnings report the stock price went down -2.088%.
Which hedge fund is a major shareholder of Immunicum AB?
Currently, no hedge funds are holding shares in DE:1YG0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology